Clinical Trial Update: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating FT-2102 in IDH1-mutant advanced solid tumors and gliomas; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma
• Glioma
• Hepatobiliary Tumors
• Intrahepatic Cholangiocarcinoma
• Other Non-central Nervous System Solid Tumors with Idh1 Mutations

Drugs mentioned

• FT-2102

Snippet

Sponsor: Forma Therapeutics, Inc. | Conditions: Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-25